Immune checkpoint inhibitors target the dysfunctional immune system, to induce cancer-cell
killing by CD8-positive T cells. Immune checkpoint inhibitors, specifically anti-CTLA4 and …

Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …

Abstract Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4
and PD-1 is associated with clinical benefit across tumor types, but also a high rate of …

Targeting checkpoints of immune cell activation has been demonstrated to be the most
effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte …

The treatment of cancer patients with immune checkpoint inhibitors (ICI)(anti-CTLA-4, anti-
PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) has without doubt …

Pancreatic ductal adenocarcinoma (PDAC) remains a lethal malignancy with an
immunosuppressive microenvironment that is resistant to most therapies. IL17 is involved in …

Checkpoint inhibitors have revolutionized cancer therapy but only work in a subset of
patients and can lead to a multitude of toxicities, suggesting the need for more targeted …

Cytosolic DNA is characteristic of chromosomally unstable metastatic cancer cells, resulting
in constitutive activation of the cGAS–STING innate immune pathway. How tumors co-opt …

PURPOSE Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (NIVO1+ IPI3) is approved for first-
line treatment of patients with advanced melanoma in several countries. We conducted a …

Background The focus of tumour-specific antigen analyses has been on single nucleotide
variants (SNVs), with the contribution of small insertions and deletions (indels) less well …